VXRT News and Press, Vaxart Inc. From 09/21/23

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET. The webcast of ...

2023-09-12 12:48:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance. With diligent research, it’s possible to...

Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection rate, a non-statistically significant reduction in norovirus acute gastroenteritis (...

2023-08-21 13:53:35 ET Despite sharp YTD declines, shares of COVID-19 vaccine makers traded higher on Monday as a newly-detected Omicron variant continued to gain ground amid a concurrent rise in COVID-related hospitalizations. Notable gainers include Novavax ( NASDAQ: NVAX ), M...

2023-08-03 19:40:20 ET Start Time: 16:30 End Time: 17:01 Vaxart, Inc. (VXRT) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and...

2023-08-03 16:06:16 ET Vaxart press release ( NASDAQ: VXRT ): Q2 GAAP EPS of -$0.16 beats by $0.02 . Revenue of $1.36M beats by $1.28M . Revenue for the second quarter of 2023 was $1.4 million, compared to no revenue in the second quarter of 2022...

On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today anno...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursd...

2023-07-06 10:33:23 ET Vaxart ( NASDAQ: VXRT ) announced Thursday that its Phase 2 clinical trial for an oral bivalent norovirus vaccine candidate met all primary endpoints, leading to strong immune responses across all dose levels. There are currently no approved vaccines for n...

Met all primary endpoints : Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023 SOUTH SAN FRANCISCO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced positive to...